Evidence map›Paper›PMID 39135587›Full record

ReviewTransactions of the American Clinical and Climatological Association2024

INSIGHTS INTO THE ORIGINS OF CYSTIC FIBROSIS LUNG DISEASE.

David A Stoltz

Abstract readReview
In one paragraph

Review in Transactions of the American Clinical and Climatological Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

David A StoltzIowa City, Iowa.

Funding

Respiratory virus infection in early cystic fibrosis lung diseaseP01HL091842 · NHLBI · UNIVERSITY OF IOWA · PI ZABNER, JOSEPH · 2008 to 2022
$34.2M
Pathology CoreP01HL152960 · NHLBI · UNIVERSITY OF IOWA · PI ENGELHARDT, JOHN F · 2020 to 2024
$11.6M
Testing the Contributions of Airway Submucosal Glands and Surface Epithelia to Lung HealthR01HL163556 · NHLBI · UNIVERSITY OF IOWA · PI STOLTZ, DAVID A · 2022 to 2025
$2.5M
NHLBI NIH HHS P01 HL091842NHLBI NIH HHS P01 HL152960NHLBI NIH HHS R01 HL163556
6 · The paper itself

Abstract

In this paper, I will discuss recent studies using a cystic fibrosis pig model to better understand the origins of cystic fibrosis lung disease. Specifically, I will review our work investigating how loss of the cystic fibrosis transmembrane conductance regulator function (CFTR) impairs mucociliary transport in the cystic fibrosis airway. These studies reveal new insights into the early, underlying mechanisms of cystic fibrosis lung disease and could lead to novel therapeutic interventions.

Indexed as

Cystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorDisease Models, AnimalMucociliary ClearanceAnimalsGenetic Predisposition to DiseaseHumansLungMutationPhenotypeSwineCFTR protein, humanCystic Fibrosis Transmembrane Conductance Regulator

Identifiers

PMID39135587
PMCPMC11316882

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.